tiprankstipranks
Alkermes presents data from phase 1b study of ALKS 2680
PremiumThe FlyAlkermes presents data from phase 1b study of ALKS 2680
2M ago
Alkermes Shareholders Approve Board Changes and Stock Plan
PremiumCompany Announcements
Alkermes Shareholders Approve Board Changes and Stock Plan
2M ago
Alkermes price target raised to $48 from $43 at Cantor Fitzgerald
PremiumThe Fly
Alkermes price target raised to $48 from $43 at Cantor Fitzgerald
2M ago
Alkermes plc Reports First Quarter 2024 Financial Results
PremiumPress ReleasesAlkermes plc Reports First Quarter 2024 Financial Results
3M ago
ALKS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALKS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Alkermes initiates Phase 2 clinical trial of ALKS 2680
PremiumThe Fly
Alkermes initiates Phase 2 clinical trial of ALKS 2680
3M ago
Alkermes narcolepsy data better than expected, says Stifel
PremiumThe FlyAlkermes narcolepsy data better than expected, says Stifel
4M ago
Alkermes Reveals Promising Phase 1b Study Results
PremiumCompany Announcements
Alkermes Reveals Promising Phase 1b Study Results
4M ago
Alkermes’ ALKS 2680 improves wakefulness in Phase 1b narcolepsy study
PremiumThe Fly
Alkermes’ ALKS 2680 improves wakefulness in Phase 1b narcolepsy study
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100